Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 7Other hematologic neoplasm 6Plasma cell 1

Conditions

Waldenstrom Macroglobulinemia 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Diseases 1

Interventions

Lenalidomide 11Dexamethasone 11fludarabine 9Cyclophosphamide 7Bortezomib 6fludarabine phosphate 5Melphalan 5pomalidomide 4isatuximab 3daratumumab 3Tacrolimus 3Mycophenolic Acid 3Busulfan 3dacetuzumab 2Whole-Body Irradiation 2Thiotepa 2Stem Cell Transplantation 2Leukapheresis 2KW-2478 2Granulocyte Colony-Stimulating Factor 2Cyclosporine 2Calcium Dobesilate 2tanespimycin 1spartalizumab 1sargramostim 1ricolinostat 1pirtobrutinib 1pembrolizumab 1nirogacestat 1ixazomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × pirtobrutinib × Plasma cell × Clear all
NCT05024045 2026-03-03

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Eli Lilly and Company

Phase 1 Active not recruiting
316 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡